- Name Roy Jefferis
- Institute University of Birmingham
Tool name: Anti-CD19 [BU12]
Alternate names: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
Tool type: Antibodies
Tool sub-type: Primary antibody
Application: FACS ; IHC ; IP
Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
Immunogen: Human EB-4 Burkitt's lymphoma cell line
Research area: Cancer; Cell signaling and signal transduction; Immunology; Stem cell biology
- For Research Use Only
- • Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475.
- • High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.
- • Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848.
- • The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
- • Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190.
- • Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin.
- • Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press
- • Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.
- • CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used.